This review discusses the evidence in support of the use of macitentan (Opsumit®), a novel
dual endothelin receptor antagonist (ERA), in the treatment of pulmonary arterial hypertension
(PAH).
Commentary by Professor Anne Keogh AM MBBS MD FRACP FCSANZ FPVRI
Joint Head of the Clinical Research Program in the Victor Chang Cardiac
Research Institute in Sydney, Australia.
Please login below to download this issue (PDF)